Copy Link Print Information

IFN-alpha 2b/IFNA2 Protein, Human

8 Cited Publications
Customer Review

Based on 8 publication(s) in Google Scholar

IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 increases the frequencies of cytotoxic CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2b/IFNA2 Protein, Human contains 165 a.a. (C24-E188), is a protein produced in E. coli with tag free.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: E. coli
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • IFN-alpha 2b/IFNA2 Protein, Human Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Biological Activity

Description

IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection[1]. IFN-alpha 2 increases the frequencies of cytotoxic CD8+ T cells and induces CD4+ T cell depletion[3]. IFN-alpha 2b/IFNA2 Protein, Human contains 165 a.a. (C24-E188), is a protein produced in E. coli with tag free.

Background

IFN-alpha 2 (IFNA2; IFN-α2), belongs to the type I interferon family, produced by the plasmacytoid dendritic cells (pDCs) exposure to HIV-1BaL in order to inhibit viral infection[1].
Interferon (IFN) is originally identified as a substance ‘interfering’ with viral replication in vitro. IFN-α/β and related molecules are classified as type I IFNs, as for the other two types of type II IFN (IFN-γ) and type III IFNs (IFN-λ), respectively[2].
IFN-alpha 2 subtype is the only one that is currently licensed to treat infections caused by hepatitis B virus (HBV) and HCV[3].
IFN-alpha 2 shows a Sortilin-dependent trafficking in cells and increases the expression level of interferon-stimulated genes (ISGs) in HIV-infected cells[1][4]. It also exhibits cytotoxic activity against CD8+ T cells and enhances CD4+ T cell depletion[3].
Among the IFN-alpha 2 alleles, IFN-alpha 2b is being the predominant allele while IFNα-2a is less predominant and IFNα-2c only a minor allelic variant[5].
IFN-alpha 2 has a bored application in research of cancer, including some hematological malignancies and solid tumors[6].

In Vivo

IFNA2a (hydrodynamic injection with plasmids) leads to upregulation of interferon-stimulated genes (ISGs) and results HIV-1 induced CD4+ T cell depletion in the hu-PBL humanized mouse model[3].

Verified Bioactivity

1.The ED50 is <0.4 ng/mL as measured by TF-1 cells, corresponding to a specific activity of >2.5 × 106 units/mg.
2.Measured in antiviral assay using A549 human lung cancer cells infected with vesicular stomatitisvirus (VSV) The ED50 for this effect is <5 ng/mL.

Technical Parameters

  • Species Human
  • Source E. coli
  • Tag Tag Free
  • Accession

    P01563 (C24-E188)

  • Gene ID
    3440  [NCBI]
  • Molecular Construction
    • N-term
    • IFNA2 (C24-E188)
      Accession # P01563
    • C-term
  • Protein Length

    Full Length of Mature Protein

  • Synonyms

    IFNA2; IFN-Alpha-2; Interferon Alpha 2; IFNA2B; IFN-AlphaA; LeIF A; IFNA; Interferon Alpha 2a; Alpha-2a Interferon; Interferon Alpha-A; Interferon Alpha 2b; Interferon 1AB4; Interferon Alpha A; IFNA2C; Interferon Alpha-2; IFNA2A

  • AA Sequence

    CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE

  • Predicted Molecular Mass

    19.4 kDa

  • Molecular Weight

    Approximately 17-20 kDa, based on SDS-PAGE under reducing conditions.

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder

Formulation

1.Lyophilized from a 0.22 μm filtered solution of PBS pH 7.4.
2.Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.2.
3.Lyophilized from a 0.22 μm filtered solution of PBS, 8% trehalose, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

References

[1]. Abraham S, et al. Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized mice. Oncotarget. 2016 Nov 29;7(48):78412-78420. [Content Brief]

[2]. Gerasymenko IM, et al. MULTIPLEX PCR ASSAY FOR DETECTION OF HUMAN SOMATOTROPIN AND INTERFERON ALPHA2b GENES IN PLANT MATERIAL. Tsitol Genet. 2015 May-Jun;49(3):3-8. [Content Brief]

[3]. Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008 Dec;226:29-40. [Content Brief]

[4]. Chang CH, et al. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b. Bioconjug Chem. 2009 Oct 21;20(10):1899-907. [Content Brief]

[5]. Sutter K, et al. Interferon α subtypes in HIV infection. Cytokine Growth Factor Rev. 2018 Apr;40:13-18. [Content Brief]

[6]. Watanabe H, et al. Detailed structure of mouse interferon α2 and its interaction with Sortilin. J Biochem. 2021 Oct 11;170(2):265-273. [Content Brief]

[7]. Gull I, et al. Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b. Springerplus. 2013 Jun 15;2(1):264. [Content Brief]

[8]. Paul F, et al. IFNA2: The prototypic human alpha interferon. Gene. 2015 Aug 10;567(2):132-7. [Content Brief]

View More

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     ≥ 95%, as determined by reducing SDS-PAGE.

  • 1/16

    MedChemExpress Validation
     Measured by its ability to inhibit proliferation of TF-1 cells. The ED50 for this effect is 0.06968 ng/mL, corresponding to a specific activity is 1.435×107 units/mg.

  • 1/16

    IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    Customer Validation
     IFN-α (1000 U/mL; 7 days). Statistical analysis of the growth curve of tumors formed by BxPC-3 cells within 31 days was performed. After BxPC-3 cells formed tumors, CD8 tiselizumab with or without IFN-α and Tα1 for 7 days was administered to the mice via tail vein injection every 4 days.

  • 1/16

    IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    Customer Validation
     IFN-α (1000 U/mL; 7 days). After BxPC3 cells formed tumors, CD8 tiselizumab with or without IFN-α and Tα1 was administered to the mice via tail vein injection every 4 days for 7 days. The protein level of CD8 in tumor specimens derived from 3 representative mice was examined by Western blotting.

  • 1/16

    IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    Customer Validation
     IFN-α (1000 U/mL; 7 days). Statistical analysis of lysed PANC-1, BXPC-3, and MIAPaCa-2 cells after coculture with CD8+ T cells was determined by a CCK8 assay. The T cells were treated with 1 μg/mL of tislelizumab in the presence or absence of IFN-α and Tα1 for 7 days and then separated and cocultured with PDAC cells for 48 h.

  • 1/16

    IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    Customer Validation
     IFN-α (1000 U/mL; 7 days). Statistical analysis of the levels of the secreted cytokines IL-2, TNF-α, and IFN-γ in suspensions of cultured CD8+ cells treated with 1 μg/mL of tislelizumab with or without the addition of IFN-α and Tα1 for 14 days was performed by ELISA.

  • 1/16

    IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    Customer Validation
     IFN-α (1000 U/mL; 7 days). Flow cytometry analysis showed PD-1 levels on CD8 Tα1.

  • IFN-alpha 2b/IFNA2 Protein, Human Product Image
    1/16
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • Experimental Validation Results for IFN-alpha 2b/IFNA2 Protein, Human
  • IFN-alpha 2b/IFNA2 Protein, Human Product Image

  • IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    IFN-α (1000 U/mL; 7 days). Statistical analysis of the growth curve of tumors formed by BxPC-3 cells within 31 days was performed. After BxPC-3 cells formed tumors, CD8 tiselizumab with or without IFN-α and Tα1 for 7 days was administered to the mice via tail vein injection every 4 days.

  • IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    IFN-α (1000 U/mL; 7 days). After BxPC3 cells formed tumors, CD8 tiselizumab with or without IFN-α and Tα1 was administered to the mice via tail vein injection every 4 days for 7 days. The protein level of CD8 in tumor specimens derived from 3 representative mice was examined by Western blotting.

  • IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    IFN-α (1000 U/mL; 7 days). Statistical analysis of lysed PANC-1, BXPC-3, and MIAPaCa-2 cells after coculture with CD8+ T cells was determined by a CCK8 assay. The T cells were treated with 1 μg/mL of tislelizumab in the presence or absence of IFN-α and Tα1 for 7 days and then separated and cocultured with PDAC cells for 48 h.

  • IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    IFN-α (1000 U/mL; 7 days). Statistical analysis of the levels of the secreted cytokines IL-2, TNF-α, and IFN-γ in suspensions of cultured CD8+ cells treated with 1 μg/mL of tislelizumab with or without the addition of IFN-α and Tα1 for 14 days was performed by ELISA.

  • IFN-alpha 2b/IFNA2 Protein, Human purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 3;28(8):113053. [Abstract]

    IFN-α (1000 U/mL; 7 days). Flow cytometry analysis showed PD-1 levels on CD8 Tα1.